Literature DB >> 22015992

Pretransplantation assessments and symptom profiles: predicting transplantation-related toxicity and improving patient-centered outcomes.

William A Wood1, Amy P Abernethy, Sergio A Giralt.   

Abstract

With the advent of reduced-intensity conditioning regimens and improvements in supportive care, hematopoietic cell transplantation (HCT) has become increasingly available to older adults and medically vulnerable populations with hematologic diseases. However, adverse outcomes including long-term treatment-related distress, disability (frailty), and death remain important concerns in this population. In other areas of oncology, comprehensive geriatric assessments have been used to stratify patients for treatment-related risk, and patient-reported outcomes (PROs) have helped in understanding treatment-related toxicity from a patient perspective. However, these powerful tools have not yet become widely used in HCT. Here, we review the theories and available data that support the development of pretreatment functional assessments and longitudinal PRO sampling in HCT. We discuss the potential for these techniques to improve transplantation outcomes through risk stratification, interventional studies, and predictive models that incorporate genetic and biomarker data. Predicting and understanding long-term transplantation-related toxicity through functional assessments and PROs will be critical to calculating the risk/benefit ratio of aggressive therapies in older patient populations, and we contend that functional assessments and PRO sampling should become standard parts of the routine evaluation of HCT patients.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22015992     DOI: 10.1016/j.bbmt.2011.10.014

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  3 in total

1.  Comparison of seven-day and repeated 24-hour recall of symptoms in the first 100 days after hematopoietic cell transplantation.

Authors:  William A Wood; Allison M Deal; Antonia V Bennett; Sandra A Mitchell; Amy P Abernethy; Ethan Basch; Charlotte Bailey; Bryce B Reeve
Journal:  J Pain Symptom Manage       Date:  2014-08-13       Impact factor: 3.612

Review 2.  Emerging uses of patient generated health data in clinical research.

Authors:  William A Wood; Antonia V Bennett; Ethan Basch
Journal:  Mol Oncol       Date:  2014-08-27       Impact factor: 6.603

3.  Comorbidity burden in patients with chronic GVHD.

Authors:  W A Wood; X Chai; D Weisdorf; P J Martin; C Cutler; Y Inamoto; D Wolff; S Z Pavletic; J Pidala; J M Palmer; M Arora; S Arai; M Jagasia; B Storer; S J Lee; S Mitchell
Journal:  Bone Marrow Transplant       Date:  2013-05-13       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.